Neurogene develops genetic medicines for rare neurological diseases, with its lead candidate aimed at Rett syndrome. NGNE reports earnings on Thu, Nov 12, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 8 | JP Morgan | Initiated | Buy | |
| Aug 12 | Canaccord Genuity | Maintained | Buy | |
| Aug 12 | Guggenheim | Maintained | Buy | |
| Aug 12 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How NGNE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in NGNE in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NGNE is in one of them and how their past NGNE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NGNE in an article yet. Here's the latest on the wider market.
About Neurogene
Neurogene is a biotechnology company based in New York that develops genetic medicines for rare neurological diseases. Its lead product candidate, NGN-401, is being studied for Rett syndrome, a severe disease that affects brain development. The company uses its proprietary EXACT technology to control how much therapeutic gene is produced in key areas of the brain. None of its products are approved for sale yet, so it does not currently generate product revenue.
- Headquarters
- New York, NY